Physician's Practice
JUNE 20, 2025
After learning that the insurance company (trying to play doctor) recommends a generic drug that is less effective and has more adverse effects because it does not carry the more expensive drug on its formulary, this gives the doctor cause for concern for their patient.
FDA Law
SEPTEMBER 6, 2021
Teva received tentative approval in June 2003 and launched in 2007 after a blocking patent expired. Especially now with the utility of the use code minimized. Amarin even sued a health insurer alleging active encouragement to use Hikma’s generic version instead of Vascepa for the patented indication.
Expert insights. Personalized for you.
52 
Let's personalize your content